122 related articles for article (PubMed ID: 35316757)
1. Single-gene diagnostic assay for rapid subclassification of basal like breast cancer with mRNA targeted antisense oligonucleotide capped molecular probe.
Moitra P; Alafeef M; Dighe K; Pan D
Biosens Bioelectron; 2022 Jul; 207():114178. PubMed ID: 35316757
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay.
Jensen TW; Ray T; Wang J; Li X; Naritoku WY; Han B; Bellafiore F; Bagaria SP; Qu A; Cui X; Taylor CR; Ray PS
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26041837
[TBL] [Abstract][Full Text] [Related]
3. FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.
Jin Y; Han B; Chen J; Wiedemeyer R; Orsulic S; Bose S; Zhang X; Karlan BY; Giuliano AE; Cui Y; Cui X
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S758-66. PubMed ID: 25124473
[TBL] [Abstract][Full Text] [Related]
4. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
Johnson J; Choi M; Dadmanesh F; Han B; Qu Y; Yu-Rice Y; Zhang X; Bagaria S; Taylor C; Giuliano AE; Amersi F; Cui X
Oncotarget; 2016 Nov; 7(46):75729-75738. PubMed ID: 27708239
[TBL] [Abstract][Full Text] [Related]
5. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.
Ray PS; Wang J; Qu Y; Sim MS; Shamonki J; Bagaria SP; Ye X; Liu B; Elashoff D; Hoon DS; Walter MA; Martens JW; Richardson AL; Giuliano AE; Cui X
Cancer Res; 2010 May; 70(10):3870-6. PubMed ID: 20406990
[TBL] [Abstract][Full Text] [Related]
6. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
7. Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer.
Chung S; Jin Y; Han B; Qu Y; Gao B; Giuliano AE; Cui X
Cell Commun Signal; 2017 Jun; 15(1):22. PubMed ID: 28629477
[TBL] [Abstract][Full Text] [Related]
8. FOXC1: an emerging marker and therapeutic target for cancer.
Han B; Bhowmick N; Qu Y; Chung S; Giuliano AE; Cui X
Oncogene; 2017 Jul; 36(28):3957-3963. PubMed ID: 28288141
[TBL] [Abstract][Full Text] [Related]
9. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling.
Wang J; Ray PS; Sim MS; Zhou XZ; Lu KP; Lee AV; Lin X; Bagaria SP; Giuliano AE; Cui X
Oncogene; 2012 Nov; 31(45):4798-802. PubMed ID: 22249250
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of FOXC1 as a therapeutic target for basal-like breast cancer.
Mott L; Su K; Pack DW
Cancer Gene Ther; 2018 May; 25(3-4):84-91. PubMed ID: 29511313
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
Choi YL; Oh E; Park S; Kim Y; Park YH; Song K; Cho EY; Hong YC; Choi JS; Lee JE; Kim JH; Nam SJ; Im YH; Yang JH; Shin YK
BMC Cancer; 2010 Sep; 10():507. PubMed ID: 20860845
[TBL] [Abstract][Full Text] [Related]
12. Forkhead box C1 promoter upstream transcript, a novel long non-coding RNA, regulates proliferation and migration in basal-like breast cancer.
Liu J; Shen L; Yao J; Li Y; Wang Y; Chen H; Geng P
Mol Med Rep; 2015 Apr; 11(4):3155-9. PubMed ID: 25516208
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
14. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
15. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.
Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB
Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858
[TBL] [Abstract][Full Text] [Related]
16. The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.
Sizemore ST; Keri RA
J Biol Chem; 2012 Jul; 287(29):24631-40. PubMed ID: 22645147
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts.
Fu P; Shen B; Zhao C; Tian G
J Nucl Med; 2010 Nov; 51(11):1805-12. PubMed ID: 20956468
[TBL] [Abstract][Full Text] [Related]
18. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
19. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.
Shepherd JH; Uray IP; Mazumdar A; Tsimelzon A; Savage M; Hilsenbeck SG; Brown PH
Oncotarget; 2016 Mar; 7(11):13106-21. PubMed ID: 26894864
[TBL] [Abstract][Full Text] [Related]
20. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
